[Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF]
- PMID: 19173805
[Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF]
Abstract
Objective: To find new serum tumor markers for ovarian epithelial cancers by 2-DE DIGE and MALDI-TOF/TOF proteomic methods, in order to improve the diagnostic sensitivity and specificity.
Methods: Serum samples from 103 cases of ovarian epithelial cancers, 60 cases of healthy women, 63 cases of benign ovarian tumors and 63 cases of benign pelvic diseases were collected. Sera of 20 cases of ovarian epithelial cancers (A), 20 cases of ovarian benign tumors (B), 20 cases of pelvic benign diseases (C) and 20 cases of health control (D) were matched by age and pooled, respectively. After depletion of high abundance serum albumin and IgG, the samples were assayed by 2-DE DIGE. The test was repeated three times. Analysis with DeCyder software revealed significant differential protein spots which were identified by MAIDI-TOF/TOF. Western blot and ELISA were used to validate the candidate serum markers.
Results: 1) There were 41 proteins having significant differences between the groups. MAIDI-TOF/TOF successfully identified 28 proteins. Haptoglobin (Hp) was the most significantly up-regulated protein, and transferrin (Tf) was the most significantly down-regulated protein. 2) Western blot and ELISA proved that there were significant differences in Hp and Tf between ovarian epithelial cancers and normal controls (P = 0.000), between ovarian epithelial cancers and ovarian benign tumors (P = 0.000), between ovarian epithelial cancers and benign pelvic disease sera (P = 0.000). 3) CA125 + Hp + Tf combined detection of ovarian cancer had higher sensitivity and specificity than CA125, Hp or Tf detection alone.
Conclusion: Hp and Tf are differently expressed in the sera of patients with ovarian epitheliual cancers. They can be used as serum biomarkers for ovarian epithelial cancers. CA125 + Hp + Tf combined detection may improve the sensitivity and specificity of diagnosis of ovarian epithelial cancers.
Similar articles
-
Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.Proteomics. 2005 Nov;5(17):4625-36. doi: 10.1002/pmic.200401321. Proteomics. 2005. PMID: 16220531
-
MALDI-TOF/TOF-MS reveals elevated serum haptoglobin and amyloid A in Behcet's disease.J Proteome Res. 2008 Oct;7(10):4500-7. doi: 10.1021/pr800279m. Epub 2008 Aug 29. J Proteome Res. 2008. PMID: 18754684
-
Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/ MALDI-TOF/TOF and data validation by routine clinical assays.Electrophoresis. 2006 Apr;27(8):1641-50. doi: 10.1002/elps.200500857. Electrophoresis. 2006. PMID: 16550499
-
Biomarker discovery for ovarian cancer using SELDI-TOF-MS.Gynecol Oncol. 2006 Jul;102(1):61-6. doi: 10.1016/j.ygyno.2005.11.029. Epub 2006 Jan 5. Gynecol Oncol. 2006. PMID: 16403569
-
Characterization of serum biomarkers for detection of early stage ovarian cancer.Proteomics. 2005 Nov;5(17):4589-96. doi: 10.1002/pmic.200500093. Proteomics. 2005. PMID: 16237736
Cited by
-
Differentially expressed proteins among normal cervix, cervical intraepithelial neoplasia and cervical squamous cell carcinoma.Clin Transl Oncol. 2015 Aug;17(8):620-31. doi: 10.1007/s12094-015-1287-x. Epub 2015 Apr 18. Clin Transl Oncol. 2015. PMID: 25893434
-
Performance of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in diagnosis of ovarian cancer: a systematic review and meta-analysis.J Ovarian Res. 2020 Jan 10;13(1):6. doi: 10.1186/s13048-019-0605-2. J Ovarian Res. 2020. PMID: 31924227 Free PMC article.
-
Circulating proteins as predictive and prognostic biomarkers in breast cancer.Clin Proteomics. 2022 Jul 11;19(1):25. doi: 10.1186/s12014-022-09362-0. Clin Proteomics. 2022. PMID: 35818030 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous